BioSyent Inc. reports strong financial results for Q1 2025.

From GlobeNewswire: 2025-05-15 17:45:00

BioSyent Inc. reported strong financial results for Q1 2025, with a 42% increase in total company sales compared to Q1 2024. Key highlights include a 21% growth in Canadian Pharma Sales, a 135% increase in International Pharma Sales, and a 52% rise in Legacy Business Sales. The company also saw a 45% growth in EBITDA and a 31% increase in Net Income After Taxes. BioSyent’s CEO, Mr. René Goehrum, emphasized the success of FeraMAX® Pd and Tibella® products, as well as the company’s focus on long-term growth and portfolio diversification. Additionally, the company announced the election of Mr. Prakash Gowd to the Board of Directors.

For more information, visit BioSyent’s investor page at www.biosyent.com/investors. The company’s Interim Unaudited Condensed Consolidated Financial Statements and Management’s Discussion and Analysis for Q1 2025 and 2024 will be available on www.sedarplus.ca on May 15, 2025. BioSyent Inc., listed on the TSX Venture Exchange under “RX,” is a specialty pharmaceutical company focused on acquiring innovative healthcare products. As of the press release date, the company has 11,254,638 common shares outstanding. Contact President and CEO Mr. René C. Goehrum for further information at [email protected] or 905-206-0013.



Read more at GlobeNewswire: BioSyent Releases Financial Results for First Quarter 2025